Dannamab and the Trailblazer All's 2 Trial

The Trailblazer All's 2 trial was published in JAMA. Dannamab is yet another antibody as opposed to the two antibodies that we've just discussed, which bind to earlier forms of A-beta aggregates before the mature plaques. Patients were treated for 76 weeks and there was about a 35% slowing of clinical decline compared to placebo. And so this trial met its primary and secondary endpoints, and is therefore a positive trial. The second clearly positive phase three trial in this class of anti-amyloid beta monoclonal antibodies.